5:29 PM
 | 
Nov 13, 2013
 |  BC Extra  |  Clinical News

Novavax reports data for H7N9 avian flu vaccine

Novavax Inc. (NASDAQ:NVAX) reported safety and immunogenicity data on Wednesday from a Phase I trial evaluating its H7N9 VLP influenza vaccine in 284 healthy adult volunteers -- the first human data for an H7N9 avian flu vaccine. In the adjuvanted arms, seroconversion rates -- defined as a four-fold increase in hemagglutinin inhibition (HAI)...

Read the full 250 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >